NEW YORK (GenomeWeb News) – Bruker reported after the close of the market Wednesday that revenues in the third quarter were $393.6 million, down less than 1 percent from $396.1 million in Q3 2015 and falling short of the consensus Wall Street estimate of $394.1 million.

Excluding a nearly 2 percent positive effect from acquisitions and, the company posted a 2 percent drop in Q3 organic growth.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.